Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
Journal of Clinical Medicine · 01.05.2023 · 12 (9) · 3247
DOI: 10.3390/jcm12093247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.05.2023. Verfasst von Kirsten E Peters und 7 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Future Fund Practitioner Fellowship.
Abstract (Originalsprache)
PromarkerD is a biomarker-based blood test that predicts kidney function decline in people with type 2 diabetes (T2D) who may otherwise be missed by current standard of care tests. This study examined the association between canagliflozin and change in PromarkerD score (Δ score) over a three-year period in T2D participants in the CANagliflozin cardioVascular Assessment Study (CANVAS). PromarkerD scores were measured at baseline and Year 3 in 2008 participants with preserved kidney function (baseline eGFR ≥60 mL/min/1.73 m2). Generalized estimating equations were used to assess the effect of canagliflozin versus placebo on PromarkerD scores. At baseline, the participants (mean age 62 years, 32% females) had a median PromarkerD score of 3.9%, with 67% of participants categorized as low risk, 14% as moderate risk, and 19% as high risk for kidney function decline. After accounting for the known acute drop in eGFR following canagliflozin initiation, there was a significant treatment-by-time interaction (p < 0.001), whereby participants on canagliflozin had decreased mean PromarkerD scores from baseline to Year 3 (Δ score: −1.0% [95% CI: −1.9%, −0.1%]; p = 0.039), while the scores of those on placebo increased over the three-year period (Δ score: 6.4% [4.9%, 7.8%]; p < 0.001). When stratified into PromarkerD risk categories, participants with high risk scores at baseline who were randomized to canagliflozin had significantly lower scores at Year 3 (Δ score: −5.6% [−8.6%, −2.5%]; p < 0.001), while those on placebo retained high scores (Δ score: 4.5% [0.3%, 8.8%]; p = 0.035). This post hoc analysis of data from CANVAS showed that canagliflozin significantly lowered PromarkerD risk scores, with the effect greatest in those T2D participants who were classified at study entry as at high risk of a subsequent decline in kidney function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Proteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.
- Medical School, The University of Western Australia, Fremantle Hospital, Fremantle, WA 6959, Australia.
- Janssen Research and Development, LLC, Spring House, PA 19477, USA.
ORCID-Profile: Kirsten E Peters, Scott D Bringans, Timothy M E Davis, Michael K Hansen
Förderung
- Medical Research Future Fund Practitioner Fellowship
Zitieren
APA
Peters, K. E., Bringans, S. D., O'Neill, R. S., Lumbantobing, T. S. C., Lui, J. K. C., Davis, T. M. E., Hansen, M. K., & Lipscombe, R. J. (2023). Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. Journal of Clinical Medicine, 12(9), 3247. https://doi.org/10.3390/jcm12093247
Vancouver
Peters KE, Bringans SD, O'Neill RS, Lumbantobing TSC, Lui JKC, Davis TME, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. Journal of Clinical Medicine. 2023;12(9):3247. doi:10.3390/jcm12093247
BibTeX
@article{Peters2023,
author = {Peters, Kirsten E and Bringans, Scott D and O'Neill, Ronan S and Lumbantobing, Tasha S C and Lui, James K C and Davis, Timothy M E and Hansen, Michael K and Lipscombe, Richard J},
title = {Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {9},
pages = {3247},
doi = {10.3390/jcm12093247}
}
EUVIMED